The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, is about to open in Xiamen. This grand event will bring together top domestic and international experts to share the latest research results and practical experiences. Ahead of the conference, Oncology Frontier interviewed Dr. Jun Guo of Peking University Cancer Hospital, who reflected on CSCO's development over the past two decades. He also introduced the key features and value of the newly updated CSCO Guidelines for Melanoma Diagnosis and Treatment and the CSCO Patient Education Manual - Melanoma. Emphasizing early detection and treatment, Professor Guo highlighted the promising outlook for melanoma therapy in China, where patients can expect improved survival rates and better quality of life thanks to the emergence of new drugs and advanced treatment concepts.

The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting was held in Xiamen from September 25 to 29, 2024. This year’s theme, “Patient-Centered, Future-Sharing,” brought together major research advancements and developments from around the world. A dedicated gastric cancer session was organized, gathering top experts in the field to explore the latest progress, technologies, and concepts in gastric cancer treatment. We invited Dr. Baorui Liu, Chair of the gastric cancer session and Director of the Oncology Center at Nanjing Drum Tower Hospital,The Affiliated Hospita of Nanjing University Medical School to share key highlights and discussions from the session.

For many years, platinum-based chemotherapy has been the cornerstone of systemic treatment for advanced urothelial cancer, such as bladder cancer. However, the release of clinical research data on antibody-drug conjugates (ADC), such as enfortumab vedotin (EV), has brought new treatment options for patients. During the 31st Urology Academic Conference held recently in Tianjin, Dr. Xin Yao from Tianjin Medical University Cancer Institute and Hospital shared insights on “Focusing on Drug Safety Management in the Era of Combined Targeted and Immunotherapy.” After the session, Urology Frontier invited Professor Yao to discuss the value of combined targeted and immunotherapy in treating urothelial cancer and the management strategies for ensuring treatment safety.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain. Key research in the field of urologic oncology garnered much attention, particularly in the area of prostate cancer. The EORTC-GUCG 1333/PEACE-3 clinical trial (LBA1 - A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3) evaluated the efficacy of Radium-223 (Ra-223) combined with enzalutamide compared to enzalutamide alone in patients with bone metastatic castration-resistant prostate cancer (mCRPC) who were asymptomatic or had mild symptoms. The promising results sparked widespread interest. Urology Frontier invited the lead investigator of the study, Dr. Silke Gillessen from the Medical Oncology of the Università della Svizzera Italiana (USI) and Oncology Institute of Southern Switzerland (IOSI), to share her insights on this important research and discuss the potential treatment outlook for bone metastatic mCRPC patients.

With the rapid advancement of medical technology, the treatment of HER2-positive breast cancer has entered a new chapter. In recent years, the emergence of anti-HER2 targeted drugs and new ADC (Antibody-Drug Conjugates) drugs has not only enriched the treatment options but also brought unprecedented hope to patients with HER2-positive breast cancer. At CSCO 2024, Oncology Frontier invited Dr. Yongmei Yin from Jiangsu Provincial Hospital to review the evolution of HER2-positive breast cancer medical treatment. From single-target therapy to dual-target treatment, and now into the era of TKI (Tyrosine Kinase Inhibitors) and ADC therapies, every step reflects the wisdom and efforts of the medical community. Professor Yin also commented on the remarkable efficacy of T-DXd in brain metastasis patients, as seen in the DB-12 study presented at the 2024 ESMO conference, and shared valuable insights on balancing efficacy and safety in clinical practice.